189 related articles for article (PubMed ID: 36630848)
1. PD-1/PD-L1 pathway: A double-edged sword in periodontitis.
Liu X; Yang L; Tan X
Biomed Pharmacother; 2023 Mar; 159():114215. PubMed ID: 36630848
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Up-Regulation in Prostate Cancer Cells by
Groeger S; Wu F; Wagenlehner F; Dansranjav T; Ruf S; Denter F; Meyle J
Front Cell Infect Microbiol; 2022; 12():935806. PubMed ID: 35846769
[TBL] [Abstract][Full Text] [Related]
3. Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions.
Groeger S; Jarzina F; Mamat U; Meyle J
Immunobiology; 2017 Feb; 222(2):137-147. PubMed ID: 28164807
[TBL] [Abstract][Full Text] [Related]
4. Porphyromonas gingivalis Cell Wall Components Induce Programmed Death Ligand 1 (PD-L1) Expression on Human Oral Carcinoma Cells by a Receptor-Interacting Protein Kinase 2 (RIP2)-Dependent Mechanism.
Groeger S; Denter F; Lochnit G; Schmitz ML; Meyle J
Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32041789
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of PD-L1 in gingival basal keratinocytes reduces periodontal inflammation in a ligature-induced periodontitis model.
Wongtim K; Ikeda E; Ohno T; Nagai S; Okuhara S; Kure K; Azuma M
J Periodontol; 2022 Jan; 93(1):146-155. PubMed ID: 34021604
[TBL] [Abstract][Full Text] [Related]
6. Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells.
Adel-Khattab D; Groeger S; Domann E; Chakraborty T; Lochnit G; Meyle J
Mol Oral Microbiol; 2021 Jun; 36(3):172-181. PubMed ID: 33715305
[TBL] [Abstract][Full Text] [Related]
7. [Expression of programmed death-1 and programmed death ligand-1 in the peripheral T-lymphocytes from patients with chronic periodontitis].
Zhu D; Liu F; Dai F; Luo X; Hong B
Zhonghua Kou Qiang Yi Xue Za Zhi; 2014 Apr; 49(4):216-9. PubMed ID: 24969595
[TBL] [Abstract][Full Text] [Related]
8. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
9.
Olsen I; Taubman MA; Singhrao SK
J Oral Microbiol; 2016; 8():33029. PubMed ID: 27882863
[No Abstract] [Full Text] [Related]
10. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
12. [Programmed death ligand 1 negatively regulates inflammatory response of chronic periodontitis].
Yuan W; Wang X; Zhang J; Zhou W; Feng Y; Chen J; Zhang P
Hua Xi Kou Qiang Yi Xue Za Zhi; 2015 Aug; 33(4):366-9. PubMed ID: 26552238
[TBL] [Abstract][Full Text] [Related]
13. [Temporal expression of PD-1 and PD-L1 during the development of experimental periodontitis in rats and its implications].
Yang X; Yang XH; Zhang WZ
Shanghai Kou Qiang Yi Xue; 2019 Dec; 28(6):591-596. PubMed ID: 32346701
[TBL] [Abstract][Full Text] [Related]
14. Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer.
Kowalski A; Malinowska K; Olszewski J; Zielińska-Bliźniewska H
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356594
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
Cassol CA; Owen D; Kendra K; Braga JR; Frankel WL; Arnold CA
Histopathology; 2020 Aug; 77(2):240-249. PubMed ID: 32298485
[TBL] [Abstract][Full Text] [Related]
16. Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).
Baglini E; Salerno S; Barresi E; Marzo T; Settimo FD; Taliani S
Mini Rev Med Chem; 2022; 22(14):1816-1827. PubMed ID: 35176979
[TBL] [Abstract][Full Text] [Related]
17. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
18. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
[TBL] [Abstract][Full Text] [Related]
19. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
